Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 7
Submit an article Journal homepage
32
Views
2
CrossRef citations to date
0
Altmetric
Miscellaneous

Prostate-specific antigen: a diagnostic marker and a tool for targeted delivery of drugs to prostate tumours

Hirak S Basu
&
Benjamin Frydman
Pages 1035-1046 | Published online: 25 Feb 2005

Bibliography

  • WANG MC, VALENZUELA LA, MURPHY GP, CHU TM: Purification of a human prostate specific antigen. Invest. Urol. (1979) 17(2):159–163.
  • •Discovery of PSA.
  • KURIYAMA M, WANG MC, PAPSIDERO LD et al.: Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. (1980) 40:4658–4662.
  • WANG MC, PAPSIDERO LD, KURIYAMA M, VALENZUELA LA, MURPHY GP, CHU TM: Prostate antigen: a new potential marker for prostatic cancer. Prostate (1981) 2(0:89–96.
  • VERNON SE, WILLIAMS WD: Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry: J. Ural. (1983) 130(l):95–98.
  • HAMDY FC, LAWRY J, ANDERSON JB, PARSONS MA, REES RC, WILLIAMS JL: Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br. J. Ural. (1992) 69(4):392–396.
  • SCARDINO PT: Early detection of prostate cancer. Urol. Clin. North (1989) 16(4):635–655.
  • EPSTEIN JI, WALSH PC, CARMICHAEL M, BRENDLER CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 271(5):368–374.
  • OHORI M, WHEELER TM, KATTAN MW GOTO Y, SCARDINO PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. Urol. (1995) 154(5):1818–1824.
  • ZIETMAN AL, EDELSTEIN RA, COEN JJ, BABAYAN RK, KRANE RJ: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology (1994) 43(6):828–833.
  • YU H, GIAI M, DIAMANDIS EP, KATSAROS D et al.: Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. (1995) 55(10):2104–2110.
  • NADJI M, TABEI SZ, CASTRO A et al.:Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer (1981) 48(5):1229–1232.
  • PAPSIDERO LD, KURIYAMA M, WANG MC etal.: Prostate antigen: a marker for human prostate epithelial cells. J. Nati Cancer Inst. (1981) 66(0:37–42.
  • QIU SD, YOUNG CY, BILHARTZ DL et al.: In situ hybridization of prostate-specific antigen mRNA in human prostate. J. Ural. (1990) 144(6):1550–1556.
  • CHRISTENSSON A, LAURELL CB, LILJA H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. Biochern. (1990) 194(3):755–763.
  • LILJA H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein: J. Clin. Invest. (1985) 76(5):1899–1903.
  • LILJA H, OLDBRING J, RANNEVIK G, LAURELL CB: Sentinel vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J. Clin. Invest. (1987) 80(2):281–285.
  • MCGEE RS, HERR JC: Human seminal vesicle-specific antigen is a substrate for human prostate-specific antigen (or P-30). Biol. Reprod. (1988) 39(2):499–510.
  • LILJA H, LAURELL CB: Liquefaction of coagulated human semen. Stand. j Clin. Lab. Invest. (1984) 44(5):447–452.
  • MCGEE RS, HERR JC: Human seminal vesicle-specific antigen during semen liquefaction Biol. Reprod. (1987) 37(2):431–439.
  • COHEN P, GRAVES HC, PEEHL DM, KAMAREI M, GIUDICE LC, ROSENFELD RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metall. (1992) 75(4):1046–1053.
  • CHRISTENSSON A, BJORK T, NILSSON 0 et al: Serum prostate specific antigen completed to al-antichymotrypsin as an indicator of prostate cancer. j Ural (1993) 150(1):100–105.
  • LILJA H, CHRISTENSSON A, DAHLEN U et al.: Prostate-specific antigen in serum occurs predominantly in complex with aI-antichymotrypsin. Clin. Chem. (1991) 37(9):1618–1625.
  • STENMAN UH, LEINONEN J, ALFTHAN H, RANNIKKO S, TUHKANEN K, ALFTHAN 0: A complex between prostate-specific antigen and al antichymotrypsin I the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. (1991) 51(0:222–226.
  • MAST AE, ENGHILD JJ, PIZZO SV, SALVESEN G: Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase complexed, and reactive site cleaved serpins: comparison of al proteinase inhibitor, al-antichymotrypsin, antithrombin 111, a2-antiplasmin, angiotensinogen, and ovalbuniin. Biochemistry (1991) 30(6):1723–1730.
  • PERLMUTTER DH, GLOVER GI, RIVETNA M, SCHASTEEN CS, FALLON RJ: Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc. Natl. Acad. Sri. USA (1990) 87(10):3753–3757.
  • LILJA H, PIIRONEN TP RITTENHOUSE HG, MIKOLAJCZYK SD, SLAWIN KM: Prostate specific antigen. In: Comprehensive textbook of genitourinary oncology Vogelzang NJ, Shipley VU, Scardino PT, Coffey DS (Eds), Lippincott Williams & Philadelphia: Wilkins Publishers. (2000):638–650.
  • HERRALA A, KURKELA R, VIHINEN M, KALKKINEN N, VIHKO P: Androgen-sensitive human prostate cancer cells, LNCAP, produce both N-terminally mature and truncated prostate-specific antigen isoforms. Eur. j Biochem. (1998) 98:32–33.
  • VEISENEN V, LOVGREN J, HELLMAN J, PIIRONEN T, LILJA H, PETTERSON K: Characterization and processing of prostate-specific antigen (hK3) and human glandular kallikrein 2 (hK2) secreted by LNCAP cells. Prostate Cancer Prostatic Dis. (1999) 2:1–7.
  • KUMAR A, MIKOLAJCZYK SD, HILL TM, MILLAR LS, SAEDI MS: Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen induced LNCaP cells. Prostate (2000) 44:248–254.
  • KUMAR A, MIKOLAJCZYK SD, HILL TM, MILLAR LS, SAEDI MS: Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. (1997) 50:31–14.
  • TAKAYAMA TK, FUJIKAWA K, DAVIE EW: Characterization of the precursor of prostate- specific antigen. _J. Biol. Chem. (1997) 272:21582–21588.
  • LOVGREN J, RAJAKOSKI K, KARP M,LUND WALL A, LILJA H: Activation of zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. (1997) 238:549–555.
  • LUND WALL A, LILJA H: Molecular cloning of human prostate specific antigen CDNA: FEBS Lett. (1987) 214(2):317–322.
  • LUND WALL A: Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem. Biophys. Res. Commun. (1989) 161(3):1151–1159.
  • RIEGMAN PH, VLIETSTRA RJ, VAN DER KORPUT JA, ROMIJN JC, TRAPMAN J: Characterization of the prostate-specific antigen gene: a novel human kallikrein like gene: Biochem. Biophys. Res. Commun. (1989) 159(0:95–102.
  • FORD TF, BUTCHOT DN, MASTERS JR, PARKINSON MC: Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br j Ural (1985) 57(9:50–55.
  • BOWMAN la, CLARK J, YU I et al: Expression, purification and characterization of deglycosylated human pro-prostate specific antigen. Protein Expr. Purif (2000) 20:405–413.
  • LOVGREN J, PIIRONEN T, OVENNO C et al: Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem. Biophys. Res. Comm. (1995) 213:888–895.
  • PETTERSON K, PIIRONEN T, SEPPALA M et al.: Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluoremetric assays for specific and sensitive detection of free PSA and PSA-al-antichymotrypsin complex. Clin. Chem. (1995) 41:1480–1488.
  • SINHA AA, SACKRISON JL, DELEON OF, WILSON MJ, GLEASON DF: Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis. Anat. Rec. (1996) 245(4):652–661.
  • MCDEVITT MR, BARENDSWAARD E, MA D et al.: An a-particle emitting antibody 4213Bi1J591) for radioimmunotherapy of prostate cancer. Cancer Res. (2000) 60(21):6095–6100.
  • SENTER PD, WALLACE PM, SVENSSON HP et al.: Generation of cytotoxic agents by targeted enzymes. Bioconjug. Chem. (1993) 4(1):3–9.
  • ANTONIW P, SPRINGER CJ, BAGSHAWE KD et al.: Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br. j Cancer (1990) 62(6):909–914.
  • DENMEADE SR, LOU W, LOVGREN J, MALM J, LILJA H, ISAACS JT: Specific and efficient peptide substrates for assaying the proteolytic activity of prostate- specific antigen. Cancer Res. (1997) 57:4924–4930.
  • •Crafting of a specific PSA substrate.
  • DENMEADE SR, NAGY A, GAO J, LILJA H, SCHALLY A, ISAACS JT: Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. (1998) 58:2537–2540.
  • KHAN SR, DENMEADE SR: In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate (2000) 45:80–83.
  • DEFEO-JONES D, GARSKY VM, WONG BK et al.: A peptide-doxorubicin `prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med. (2000) 6 (11):1248–1252.
  • •Crafting of a specific PSA substrate.
  • JAKOBSEN CM, DENMEADE SR, ISAACS JT, GADY A, OLSEN CE, CHRISTENSEN SB: Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apopotosis to prostatic cancer cells. j Med. Chem. (2001) 44:4696–4703.
  • DENMEADE SR, SOKOLL LJ, CHAN DW, KHAN SR, ISAACS JT: Concentration of enzymatically active prostate-specific antigen ( PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate (2001) 48:1–6.
  • FRYDMAN B, MARTON LJ, SUN JS et al.: Induction of DNA topoisomerase II-mediated DNA: cleavage by P-lapachone and related naphthoquinones. Cancer Res. (1997) 57:620–627.
  • DOLAN ME, FRYDMAN B, THOMPSON CB et al: Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. Anticancer Drugs (1998) 9:437–448.
  • CHANG SS, REUTER VE, HESTON WD, GAUDIN PB: Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology (2001) 57(6):1179–1183.
  • O'KEEFE DS, UCHIDA A, BACICH DJ et al.: Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate (2000) 45(2):149–157.
  • WILLIAMS-ASHMAN HG, CANELLAKIS ZN: Polyamines in mammalian biology and medicine. Persp. Biol. Med. (1997) 421–453.
  • •A comprehensive review of polyamines and reproduction.
  • FRYDMAN B, VALASINAS A: Polyamine-based chemotherapy of cancer. Expert Opin. Ther. Patents (1999) 9(8):105–168.
  • REDDY VK, VALASINAS A, SARKAR A, BASU HS, MARTON LJ, FRYDMAN B: Conformationally restricted analogues of N1, N12-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. J. Med. Chem. (1998) 41:4723–4732.
  • VALASINAS A, SARKAR A, REDDY VK, MARTON LJ, BASU HS, FRYDMAN B: Conformationally restricted analogues of NI, N14-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells. j Med. Chem. (2001) 44(3):390–403. Synthesis of SL–11093.
  • REDDY VK, SARKAR A, VALASINAS A, MARTON LJ, BASU, FRYDMAN B: Cis-Unsaturated analogues of 3,8,13,18,23-pentaazapentacosane (BE-4-4-4-4): Synthesis and growth inhibitory effects on human prostate cancer cell lines. j Med. Chem. (2001) 44(3):404–117.
  • KABRA PM, LEE HK, LUBICH WI MARTON LJ: Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography:improved separation systems for polyamines in cerebrospinal fluid, urine, and tissue. j Chromatog. (1986) 380:19–32.
  • COHEN SS: A Guide to the polyamines, Oxford University Press, Oxford, UK. (1998):208–232.
  • ••A comprehensive review on polyamines.
  • BERGERON RJ, WEIMAR WR, LUCHETTA G, SNINSKY CA, WEIGAND J: Metabolism and pharmacokinetics of N1,N14 diethylhomospermine. Drug Metabol Disposition (1996) 24:334–343.
  • •Detailed insight in polyamine metabolism.

Websites

  • AMERICAN CANCER SOCIETY: How many men get prostate cancer? http://www.cancenorg

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.